AveXis, Inc., a Novartis Company

[Not Yet Scheduled]
AveXis, a Novartis company, is the world’s leading gene therapy company, redefining the possibilities for patients and families affected by life-threatening genetic diseases through our innovative gene therapy platform. Founded in 2013 and headquartered in Bannockburn, IL, the goal of AveXis’ cutting-edge science is to address the underlying, genetic root cause of diseases. AveXis pioneered foundational research, establishing AAV9 as an ideal vector for gene transfer in diseases affecting the central nervous system, laying the groundwork to build a best-in-class, transformational gene therapy pipeline. AveXis received its first U.S. Food and Drug Administration approval in May 2019 for the treatment of spinal muscular atrophy (SMA). AveXis is also developing therapies for other genetic diseases, including Rett syndrome and a genetic form of amyotrophic lateral sclerosis (ALS) SOD1.
Ticker:
NVS
Exchange:
NYSE
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Illinois
Company HQ Country:
United States
Year Founded:
2013
Main Therapeutic Focus:
Lead Product in Development:
Zolgensma® (onasemnogene abeparvovec-xioi)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
SVP and Chief Scientific Officer, AveXis
AveXis, Inc., a Novartis Company